In their lawsuit, BMS and Ono accuse Amgen of aiming to market its biosimilar ahead of the expiration of key U.S. patents ...

Bristol Myers Squibb and Ono Pharmaceutical, the US and Japanese pharma majors that co-developed Opdivo (nivolumab), have ...

Bristol Myers Squibb and Ono Pharmaceutical have sued Amgen in Delaware federal court, seeking to block Amgen's proposed U.S.

On 8, 2026, Bristol-Myer’s Squibb filed BPCIA Case No. 1:26-cv-01134 (D. Del.) against Amgen’s proposed Opdivo® (nivolumab) biosimilar ...

On July 24, 2025, the PTO Acting Director Coke Morgan Stewart discretionarily denied Amgen’s IPR2025-00601 and IPR2025-00602 challenging Bristol-Myers Squibb’s (“BMS”) U.S. Patent Nos. 9,856,320 (“the ...

NIVORZ is a biosimilar version of Bristol Myers Squibb's (BMS) blockbuster drug Opdivo (nivolumab) and has been approved by the Drugs Controller General of India (DCGI) across 12 cancer indications, ...

MONTREAL, Dec. 17, 2025 /CNW/ - Bristol Myers Squibb Canada (BMS) today announced that Canada's Drug Agency (CDA-AMC) has issued a positive reimbursement recommendation for OPDIVO® (nivolumab) in ...

Add Yahoo as a preferred source to see more of our stories on Google. The EC approval is based on the Phase II CheckMate-744 trial in classical Hodgkin Lymphoma patients. Credit: Saiful52 / ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Opdivo from Bristol-Myers Squibb sits in a chilled infusion bag on a stainless-steel tray, the clear solution catching the harsh white light of an oncology center as a nurse double-checks the ...